Rifapentine
FDA-approved product (tablet, oral), marketed as Priftin, Rifapentine.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 4 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Tuberculosis
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Antibiotics
- FDA pharmacologic class
- Rifamycin Antimycobacterial FDA label ↗
- Anti-infective classification
- Classified as an existing antimicrobial.WHO ATC J04AB05; FDA class Rifamycin Antimycobacterial
Repurposing investigation
Rifapentine is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.
AI-predicted activity
AI prediction · nothing measured- MRSA98.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
- E. coli76.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- M. tuberculosis95.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. A stereoisomer of this medicine was in the model's training data.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Rifapentine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- UrsodiolExisting use: Biliary liver cirrhosis, Primary biliary cirrhosis69.2% AI-predicted activityagainst MRSA50+ registered studies
- OlaparibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 9 more69.2% AI-predicted activityagainst MRSA50+ registered studies
- Ganirelix AcetateExisting use: Female infertility, Positive regulation of ovulation, Reproductive Techniques, Assisted69.1% AI-predicted activityagainst MRSA50+ registered studies
- DanicopanExisting use: Acquired paroxysmal nocturnal hemoglobinuria, Hemoglobinuria, Paroxysmal, Hemolysis68.7% AI-predicted activityagainst MRSA30 registered studies
- Simeprevir SodiumExisting use: Chronic hepatitis C virus infection68.6% AI-predicted activityagainst MRSANo documented evidence found
- Lanreotide AcetateExisting use: Acromegaly, Carcinoid syndrome68.3% AI-predicted activityagainst MRSA50+ registered studies
- Cholic AcidExisting use: Abnormality of the gastrointestinal tract, Inborn errors of metabolism, Liver disease and 1 more68.0% AI-predicted activityagainst MRSA50+ registered studies
- EptifibatideExisting use: Acute coronary syndrome, Acute myocardial infarction, Intermediate coronary syndrome and 2 more67.8% AI-predicted activityagainst MRSA35 registered studies
- AbarelixExisting use: Neoplasm67.7% AI-predicted activityagainst MRSA5 registered studies
- EverolimusExisting use: Adenoma sebaceum, Anaplastic astrocytoma, Angiomyolipoma and 18 more67.5% AI-predicted activityagainst MRSA50+ registered studies
- Paliperidone PalmitateExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.3% AI-predicted activityagainst MRSA50+ registered studies
- PaliperidoneExisting use: Mental or behavioural disorder, Psychosis, Schizoaffective disorder and 1 more67.2% AI-predicted activityagainst MRSA50+ registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine
NCT00460759 · start 2007-06
Registered record
- Registry ID
- NCT00460759
- Conditions
- Mycobacterium Tuberculosis
- Interventions
- Moxifloxacin; Rifapentine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Terminated
- Start
- 2007-06
- Completion
- 2008-08-24
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionMycobacterium TuberculosisInterventionMoxifloxacin; RifapentinePhasePhase 1Registry statusTerminatedTBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection
NCT00164450 · start 2005-09
Registered record
- Registry ID
- NCT00164450
- Conditions
- Tuberculosis
- Interventions
- Isoniazid; Rifapentine
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2005-09
- Completion
- 2008-08
- Enrolment
- 158
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosisInterventionIsoniazid; RifapentinePhaseNot applicableRegistry statusCompletedThree Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
NCT00023452 · start 2001-06
Registered record
- Registry ID
- NCT00023452
- Conditions
- Tuberculosis
- Interventions
- RPT + INH once weekly for 3 months given by DOT; Isoniazid (INH) daily for 9 months
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2001-06
- Completion
- 2013-09
- Enrolment
- 8,053
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosisInterventionRPT + INH once weekly for 3 months given by DOT; Isoniazid (INH) daily for 9 monthsPhasePhase 3Registry statusCompletedTBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine
NCT00023387 · start 2000-03
Registered record
- Registry ID
- NCT00023387
- Conditions
- Tuberculosis
- Interventions
- Rifapentine; 25-desacetyl Rifapentine; Isoniazid
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2000-03
- Completion
- 2001-05
- Enrolment
- 36
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosisInterventionRifapentine; 25-desacetyl Rifapentine; IsoniazidPhaseNot applicableRegistry statusCompletedTBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis
NCT00023426 · start 1999-07
Registered record
- Registry ID
- NCT00023426
- Conditions
- Tuberculosis
- Interventions
- rifapentine
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 1999-07
- Completion
- 2003-02
- Enrolment
- 150
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionTuberculosisInterventionrifapentinePhasePhase 2Registry statusCompleted